The formation of tubular structures by endothelial cells is under the control of fibrinolysis and mechanical factors
Tóm tắt
This study highlights the importance of several factors involved in the formation of capillary-like structure formation (CLS) using Human Umbilical Vein Endothelial Cells (HUVEC) and Bovine Retinal Endothelial Cells (BREC) cultured on fibrin gels. The fibrin concentration inducing (CLS) was 0.5 mg/ml for HUVEC and 8 mg/ml for BREC. The high fibrin concentration required for the latter cells appeared necessary to counterbalance the extensive fibrinolysis of the gel by the BREC. Fibrin degradation products measured in the culture media showed that fibrin degradation was mandatory but not sufficient for CLS formation. Fibrin degradation acted in concert with the mechanical, concentration dependent properties of the gels to induce CLS. For example, HUVEC did not form CLS on a rigid fibrin of 8 mg/ml in spite of fibrinolysis. As cell reorganisation occurred, the fibrin was disrupted (HUVEC) or pleated (BREC) giving indirect proof of the development of mechanical forces. During CLS formation, an increasing amount of latent TGFβ1 was measured in the medium (1000–1700 pg/ml). The active form of TGFβ1 was not, however, detected and the addition of anti-TGF-β1 antibody to the medium did not influence the formation of the CLS network. Yet, added activated TGF-β1 led to the formation of less organised structures, that were completely abolished by the concomitant addition of the same anti-TGF-β1 antibody. Thus, it is likely that TGF-β1 secreted by the endothelial cells remained in its latent form. In conclusion, a balance between the mechanical properties of fibrin and the fibrinolytic activity of each cell type may regulate CLS formation in our models. We think that the high fibrinolitic activity of the BREC may represent a defense mechanism to protect the retina against thrombosis-induced damage in vivo.
Tài liệu tham khảo
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1, 27–31.
Madri JA, Sankar S, Romanic AM. Angiogenesis. In: Clark RAF (ed), The Molecular and Cellular Biology of Wound Repair, 2nd edn. New York: Plenum Press, 1996; 355–371.
O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2, 689–692.
Brooks PC. Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev 1996; 15, 187–194.
Pepper MS, Montesano R, Mandriota SJ, et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996; 49, 138–162.
Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980; 288, 551–556.
Montesano R, Vassalli JD, Bird A, et al. Basic fi-broblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83, 7297–7301.
Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 1990; 63, 115–122.
Vernon RB, Lara SL, Drake CJ, et al. Organized type I collagen influences endothelial patterns during `spontaneous angiogenesis in vitro', planar cultures as models of vascular development. In vitro Cell Dev Biol 1995; 31, 120–131.
Chalupowicz G, Chowdhury ZA, Bach TL, et al. Fibrin II induces endothelial cell capillary tube formation. J Cell Biol 1995; 130, 207–215.
Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988; 107, 1589–1598.
Nicosia RF, Bonanno E, Smith M, Yurchenco P. Modulation of angiogenesis in vitro by laminin-entactin complex. Dev Biol 1994; 164, 197–206.
Davis GE, Camarillo CW. Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp Cell Res 1995; 216, 113–123.
Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989; 58, 803–805.
Ingber DE. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech 1995; 28, 1471–1484.
Vernon RB, Sage EH. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 1995; 147, 873–883
Vailhé B, Ronot X, Tracqui P, et al. In vitro angiogenesis is modulated by the mechanical properties of fibrin and is related to αvbβ integrin localisation. In Vitro Cell Dev Biol 1997; 33, 763–773.
Dubois-Stringfellow N, Jonczyck A, Bautch VL. Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organisation of cultured murine endothelial cells. Blood 1994; 83, 3206–3217.
Vassalli JD, Sappino AP, Belin D. The plasminogen activitor/plasmin system. J Clin Invest 1991; 88, 1067–1072.
Lijnen HR, Bachmann F, Collen D, et al. Mechanisms of plasminogen activation. J Int Med 1994; 236, 415–424.
Wang N, Planus E, Pouchelet M, et al. Urokinase receptor mediates mechanical force transfer across the cell surface. Am J Physiol 1995; 268, C1062–C1066.
Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9, 919–925.
Montesano R, Vassali JD, Orci L, Pepper MS. The role of growth factors and extracellular matrix in angiogenesis and epithelial morphogenesis. In Sizonenko PC, Augert ML and Vassali JD (eds), Developmental Endocrinology, Frontiers in Endocrinology. Rome: Ares-Serono Symposia Publications, 1994; 6, 43–66.
Mandriota SJ, Menoud PA, Pepper MS. Transforming growth factor β1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J Biol Chem 1996; 271, 11500–11505.
Sporn MB, Roberts AB. Transforming growth factor-b: recent progress and new challenges. J Cell Biol 1992; 119, 1017–1021.
Lawrence DA. Transforming growth factor-β: a general review. Eur Cytokine Netw 1996; 7, 363–374.
Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990; 110, 1361–67.
Bizik J, Felnerova D, Grofova M, Vaheri A. Active transforming growth factor-β in human melanoma cell lines: no evidence for plasmin-related activation of latent TGF-β. J Cell Biochem 1996; 62, 113–122.
Pepper MS, Vassalli JD, Orci L, Montesano R. Angiogenesis in vitro, cytokines interactions and balanced extracellular proteolysis. In: Maragoudakis ME (ed), Angiogenesis: Molecular Biology, Clinical Aspects. New-York: Plenum Press, 1994; 149–170.
Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20, 1–5.
Keckwick RA, McKay ME, Nance MH, Record BR. The purification of human fibrinogen. Biochem J 1955; 60, 671–683.
Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254, 5357–5363.
Jaffé EA, Nachman ARL, Becker CG, Minnick CR. Culture of human endothelial cells derived from umbilical veins, identification by morphologic and immunologic criteria. J Clin Invest 1973; 52, 2745–2756.
Lecomte M, Paget C, Ruggiero D, et al. Docosahexaenoic acid is a major n-3 polyunsaturated fatty acid in bovine retinal microvessels. J Neurochem 1996; 66, 2160–2167.
Heimer GV, Taylor CED. Improved mountant for immunofluorescence preparations. J Clin Pathol 1974; 27, 254–256.
Osborn M, Weber K. Immunofluoresence and immunocytochemical procedures with affinity purified andibodies: tubuline containing structures. Methods Cell Biol 1982; 24, 97–132.
Schnaper HW, Barnathan ES, Mazar A, et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165, 107–118.
Pepper MS, Vassalli JD, Montesano R, Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105, 2353–2541.
Koolwijk P, Van Erck MG, De Vree WJ, et al. Cooperative effect of TNF alpha, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132, 1177–1188.
Thompson WD, Stirk CM, Melvin WT, Smith EB. Plasmin, fibrin degradation and angiogenesis. Nat Med 1996; 2, 493.
Rymaszewski Z, Szymanski PT, Ablanalp W, et al. Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose. Proc Soc Exp Biol Med 1992; 199, 183–191.
Ferry JD. Structure and Rheology of fibrin networks. In: Kramer O (ed), Biological and Synthetic Polymer Networks. London: Elsevier, 1988; 41–55.
Ferrenq I, Tranqui L, Vailhé B, et al. Modelling biological gel contraction by cells: mechanocellular formulation and cell traction force quantification. Acta Biotheoretica 1997; 45, 267–293.
Ingber DE. Integrins as mechanochemical transducers. Curr Opin Cell Biol 1991; 3, 841–848.
Cheresh D. Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Nat Acad Sci USA 1987; 84, 6471–6475.
Henke CA. Intra-alveolar fibrosis. Alpha v beta 3 integrin and chondroitin sulfate proteoglycan mediate endothelial cell adhesion, migration, and invasion into the provisional matrix. Chest 1994; 105 (suppl), 121S.
Myohanen HT, Stephens RW, Hedman K, et al. Distribution and lateral mobility of urokinase-receptor complex at the cell surface. J Histochem Cytochem 1993; 41, 1291–1301.
Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224, 344–353.
Tada K, Fukunaga T, Wakabayashi Y, et al. Inhibition of tubular morphogenesis in human microvascular endothelial cells by co-culture with chondrocytes and involvement of transforming growth factor β: a model for avascularity in human cartilage. Biochem Biophys Acta 1994; 1201, 135–142.
Choi ME, Ballerman BJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors. J Biol Chem 1995; 270, 21144–21150.
Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 1993; 204, 356–363.
Vailhé B, Tranqui L. The role of transforming growth factor-β1 (TGF-β1) and of vascular endothelial growth factor (VEGF) on the in vitro angiogenesis process. CR Acad Sci Paris, Life Sciences (série III) 1996; 319, 1003–10.
Pepper MS, Belin D, Montesano R, et al. Transforming growth factor-beta1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111, 743–755.
Pepper MS, Montesano R, Orci L, Vassalli JD. Plasminogen activator inhibitor-1 is induced in microvascular endothelial cells by a chondrocytederived transforming growth factor-beta. Biochem Biophys Res Commun 1991; 176, 633–638.
Merwin JR, Anderson JM, Kocher O, et al. Transforming growth factor beta 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 1990; 142, 117–128.
Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by transforming growth factor-β depends upon the composition and organization of the extracellular matrix. J Cell Biol 1988; 106, 1375–1384.
RayChaudhury A, D'Amore PA. Endothelial cell regulation by transforming growth factor-beta. J Cell Biochem 1991; 47, 224–229.